Analysis of new cancer drug trial shows patients had a 55% likelihood of remaining alive without disease progression at seven years
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer – Company Announcement - FT.comThe latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.markets.ft.com